多发性骨髓瘤患者接受 CAR T 细胞治疗后
Sending CAR T Cells After Multiple Myeloma.
出版信息
Cancer Discov. 2017 Aug;7(8):OF9. doi: 10.1158/2159-8290.CD-NB2017-088. Epub 2017 Jun 6.
Abstract
Preliminary results from an ongoing phase I clinical trial in China suggest that chimeric antigen receptor T cells engineered to home in on a protein called BCMA may be a potent therapeutic option for multiple myeloma. The therapy was well tolerated and induced complete, durable responses in patients with relapsed/refractory disease.
摘要
中国正在进行的一项 I 期临床试验的初步结果表明，针对一种名为 BCMA 的蛋白而设计的嵌合抗原受体 T 细胞可能是多发性骨髓瘤的一种有效治疗选择。该疗法耐受性良好，并在复发/难治性疾病患者中诱导出完全、持久的反应。
Zotero 插件